A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer

Condition:   Carcinoma, Non-Small-Cell Lung Interventions:   Drug: Tislelizumab;   Drug: Concurrent chemoradiotherapy (cCRT);   Other: Placebo Sponsors:   Celgene;   BeiGene Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials